Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (446)	3/10/2003 6:25:00 PM
From: SemiBull	Read Replies (1) \| Respond to of 513

Avant Immunotherapeutics in Pact With Pharmacia Monday March 10, 11:31 am ET NEEDHAM, Mass. (Dow Jones)--Avant Immunotherapeutics Inc. agreed to purchase patent applications and other properties dealing with anti- atherosclerosis drugs from Pharmacia Corp. (NYSE:PHA - News) for undisclosed terms. In a press release Monday, Avant said the acquisition, coupled with a similar purchase in September 2001, consolidates its ownership of patent applications that cover the technology of anti-atherosclerosis vaccines. Atherosclerosis is the process by which different types of fatty substances, or plaque, build up in the inner lining of the artery. It is the underlying cause of heart attacks and strokes. These purchased properties deal specifically with methods or products that stimulate an immune response against cholesterol ester transfer proteins, or CETPs. Avant owns a CETi-1 cholesterol management system, which is designed to raise serum HDL, or "good cholesterol" levels by blocking the transfer of cholesterol from HDL to LDL, or "bad" cholesterol. CETP is the agent that transfers HDL to LDL. The Pharmacia properties deal specifically with the CETP agent. -Thomas Derpinghaus; Dow Jones Newswires; 201-938-5388